Menu

AQUADEX
SMARTFLOW®
SYSTEM

EFFECTIVE FLUID MANAGEMENT

The Aquadex SmartFlow System is FDA cleared to simply, safely, and precisely remove excess fluid (primarily salt and water) from patients suffering from Fluid Overload who have not responded to medical management, including diuretics.

CLINICALLY PROVEN SOLUTION
FOR TREATING FLUID OVERLOAD

Providers can specify and adjust the rate of fluid removed for each individual patient, resulting in a gradual reduction of excess fluid. Up to 500 mL per hour of excess fluid can be removed. Aquadex® therapy has been shown to have no significant clinical impact on blood pressure, heart rate, or the balance of electrolytes (e.g., sodium, potassium, etc.) in the body – as compared to patients’ own baselines as well as compared to usual care for hospitalized patients with heart failure.1,2

Review the clinical data for Aquadex therapy here.

PREDICTABLE IN OUTCOMES

Aquadex SmartFlow System
Simple

Simple

  • Easy set-up and monitoring allows for up to 4:1 patient to nurse ratio
  • Highly automated with only one setting required to begin
  • Smart alarms/alerts prompt action when necessary
Flexible

Flexible

  • Perform therapy through peripheral or central venous access
  • Portable system with small 35 ml extracorporeal volume meets patient needs in a multitude of clinical settings
  • Customizable hematocrit (Hct) monitor can be tailored to individual patient needs
Smart

Smart

  • Hct sensor provides real-time measurement of percent blood volume change
  • SvO2 monitoring provides insights into tissue oxygen delivery
  • Filter Alert prompts action to extend filter life and reduce therapy time

SYSTEM COMPONENTS

The Aquadex SmartFlow System consists of three components, the console, the peripheral catheter, and the blood circuit set. The console allows caregivers precise control of ultrafiltration therapy. The peripheral catheter draws blood from and returns blood to the patient. Finally, the blood circuit set filters the patient’s blood and collects excess water and salt.

pdf

Aquadex Console

Product Brochure

pdf

Aquadex Peripheral Catheter

Product Brochure

pdf

Aquadex Blood Circuit Set

Product Brochure

AQUADEX SMARTFLOW® SOFTWARE RELEASE NOTES

Hct Graph

If the Hct sensor clip is removed from the blood circuit for a few minutes, the resulting graph will show the “no data” points inconsistently depending on the selected time base on the horizontal axis. The user is given an alarm if the Hct clip is not on the cuvette, minimizing the likelihood of this occurring.

Auto Flow Rate Change

The Aquadex System does not allow the Ultrafiltrate Rate (UF) to be more than 21% of the Blood Flow (BF) rate. For example, setting BF to 40 ml/min and UF rate to 500 ml/hr puts the UF at 21% of BF. In this situation, if the user chooses to further decrease BF, the UF will automatically decrease to remain at no more than 21% of BF with the message “Current blood flow rate requires UF rate to be decreased”. The message only displays the first time the rate is automatically changed.

Software Version 2.0.1

Version 2.0.1 is an international release of the SmartFlow software, updated to support additional languages. The functionality of the software is identical to version 2.0.0 – please refer to the release notes for that version.

[1] RAPID Trial: Bart BA, et al. J Am Coll  Cardiol. 2005 Dec 6; 46(11): 2043-2046. [2] SAFE Trial: Jaski BE, et al. J Card Fail. 2003 Jun; 9(3): 227-231.

Rx Only. Indication: Continuous ultrafiltration therapy for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a healthcare provider, within an outpatient or inpatient clinical setting, under physician prescription, both of whom having received training in extracorporeal therapies.

jump